Company: JUNS
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001641172-25-001261
Chunk: 913

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 2
Chunk 913
---
 as they relate to us or the Company’s management, identify
forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and
information currently available to, the Company’s management. Actual results could differ materially from those contemplated by
the forward-looking statements as a result of certain factors detailed in our filings with the SEC.

The
following discussion and analysis of our financial condition and results of operations should be read in conjunction with the financial
statements and the notes thereto contained elsewhere in this Annual Report on Form 10-K. Certain information contained in the discussion
and analysis set forth below includes forward-looking statements that involve risks and uncertainties. Unless the context otherwise requires,
“JNS,” “we,” “us,” “our,” or the “Company” refers to Jupiter Neurosciences,
Inc.

Business
Overview

We are a clinical stage research and development company.
We have developed a unique resveratrol platform product primarily targeting treatment of neuro-inflammation. Our platform product, JOTROL,
an enhanced oral formulation of resveratrol, has many potential indications of use for rare diseases. In the larger disease areas, we
are primarily targeting Parkinson’s Disease and Mild Cognitive Impairment/early Alzheimer’s disease.

In December 2024, we received gross proceeds of $11
million in a registered public offering (“Public Offering”) of 2,750,000 shares of our common stock, par value $0.0001 per
share (“common stock”) at a price of $4.00 per share for gross proceeds of $11 million before deducing underwriting discounts
and other related expenses. In connection with the Public Offering, the Company’s common stock was registered under Section 12(b)
of the Exchange Act and began trading on The Nasdaq Capital Market under the symbol “JUNS.”

Business Overview

The Company’s platform product, JOTROL, is an
enhanced orally administered resveratrol formulation designed and intended to deliver therapeutically relevant, safe levels of resveratrol.
This platform has many potential indications of use for rare diseases, which include Mucopolysaccharidoses Type 1, Friedreich’s
ataxia and MELAS. In the larger disease areas, we are primarily targeting Parkinson’s Disease and Mild Cognitive Impairment/early
Alzheimer’s disease.

The present primary target for the Company is
treatment of Parkinson’s Disease (PD). The Company completed preclinical activities in